What is the 13F Pro Quality Score for POCI?

13F Pro ranks PRECISION OPTICS CORPORATION, INC. (POCI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View POCI's current score at https://13fpro.ai/research/POCI (free sign-up required for the full ranking).

Where does 13F Pro source POCI data?

All PRECISION OPTICS CORPORATION, INC. fundamentals and ownership data come directly from SEC EDGAR. PRECISION OPTICS CORPORATION, INC. files with the SEC under CIK 867840. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is POCI in?

PRECISION OPTICS CORPORATION, INC. (POCI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is POCI research updated on 13F Pro?

POCI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PRECISION OPTICS CORPORATION, INC.(POCI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 867840 POCI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $21.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

POCI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PRECISION OPTICS CORPORATION, INC. (POCI), a Healthcare sector company. POCI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $21.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), PRECISION OPTICS CORPORATION, INC. reports quarterly revenue of $8.7M, net income of $-108.3K, free cash flow of $-723.3K. Top institutional holders of POCI by reported 13-F value include NEEDHAM INVESTMENT MANAGEMENT, MYDA Advisors, Nantahala Capital Management,, based on the most recent SEC filings. POCI trades on the Nasdaq exchange and files with the SEC under CIK 867840. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate POCI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRECISION OPTICS CORPORATION, INC. directly from SEC EDGAR.

Revenue

Q3 2026

$8.7M

Net Income

Q3 2026

$-108.3K

Free Cash Flow

Q3 2026

$-723.3K

D/E Ratio

Q3 2026

0.10

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-0.1% YoY

$19.1MFY 2025

FY22 $15.7MFY23 $21.0MFY24 $19.1MFY25 $19.1M

Net Income

-95.8% YoY

$-5.8MFY 2025

FY22 $-928.4KFY23 $-144.6KFY24 $-3.0MFY25 $-5.8M

Operating Income

-103.8% YoY

$-5.6MFY 2025

FY22 $-1.5MFY23 $-638.5KFY24 $-2.7MFY25 $-5.6M

EPS (Diluted)

-73.5% YoY

$-0.85FY 2025

FY22 $-0.18FY23 $-0.03FY24 $-0.49FY25 $-0.85

Total Assets

+17.0% YoY

$19.8MFY 2025

FY22 $16.7MFY23 $19.7MFY24 $16.9MFY25 $19.8M

Total Debt

+0.9% YoY

$2.5MFY 2025

FY22 $2.7MFY23 $3.2MFY24 $2.5MFY25 $2.5M

Op. Cash Flow

-32.2% YoY

$-3.5MFY 2025

FY22 $-933.4KFY23 $-81.1KFY24 $-2.7MFY25 $-3.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$19.1M -0.1%	$19.1M -9.2%	$21.0M +34.2%	$15.7M +46.9%	$10.7M +7.6%	$9.9M
Net Income	$-5.8M -95.8%	$-3.0M -1940.9%	$-144.6K +84.4%	$-928.4K -802.8%	$-102.8K +92.8%	$-1.4M
Operating Income	$-5.6M -103.8%	$-2.7M -326.6%	$-638.5K +57.8%	$-1.5M -67.2%	$-905.6K +36.4%	$-1.4M
EPS (Diluted)	$-0.85 -73.5%	$-0.49 -1533.3%	$-0.03 +83.3%	$-0.18 -1700.0%	$-0.01	—
Total Assets	$19.8M +17.0%	$16.9M -14.3%	$19.7M +18.2%	$16.7M +166.8%	$6.3M -1.4%	$6.4M
Total Debt	$2.5M +0.9%	$2.5M -23.4%	$3.2M +19.3%	$2.7M	$0.00	—
Operating Cash Flow	$-3.5M -32.2%	$-2.7M -3208.7%	$-81.1K +91.3%	$-933.4K -2105.1%	$46.5K +107.9%	$-592.5K

AI Insight: POCI Financial Trends

Revenue grew 80% from Q2 2024 to Q1 2026, but company remains unprofitable with operating losses in every quarter and deteriorating equity volatility.

• Revenue climbed from $5M in Q2 2024 to $9M in Q1 2026, with Q3 2025 and Q4 2025 stabilizing at $7M before acceleration.

• Operating losses narrowed from -$1M to -$2M range (Q2 2024–Q4 2025) to breakeven in Q1 2026, showing margin improvement.

• Total debt fell from $3M (Q1 2025, Q2 2025) to $2M in Q1 2026, reducing leverage despite unprofitability.

⚠ Equity spiked 81% from $11M (Q3 2025) to $20M (Q1 2026)—likely dilutive financing masking cash burn.

⚠ Company has posted net losses every quarter; Q1 2026 breakeven is single-quarter data point without confirmed sustain.

⚠ Operating cash flow remains negative or flat across all eight quarters; no positive conversion despite revenue growth.

AI Insight: POCI Ratio Trends

Q1 2026 shows dramatic profitability inflection—operating margin swung from -23.6% to -0.7%, approaching breakeven after nine consecutive loss-making quarters.

• Operating margin improved 22.9pp from Q4 2025 (-23.6%) to Q1 2026 (-0.7%), signaling potential path to profitability.

• Net profit margin narrowed to -1.2% in Q1 2026 from -24.2% in Q4 2025; all return metrics similarly recovered toward zero.

• Leverage remained stable; D/E dropped to 0.10 in Q1 2026 from 0.24 in Q4 2025, lowest in the dataset.

⚠ Q1 2026 profitability may reflect seasonal strength or one-off items; TTM metrics still deeply negative (-16.4% OpMargin, -21.5% ROIC).

⚠ Confirm whether margin recovery is sustainable; company burned cash through Q4 2025 with persistent operating losses.

Get alerted when POCI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PRECISION OPTICS CORPORATION, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of POCI

NEEDHAM INVESTMENT MANAGEMENT LLC
$7.3M1,670,550 sh
MYDA Advisors LLC
$1.8M400,000 sh
Nantahala Capital Management, LLC
$1.2M280,000 sh
Bleichroeder LP
$1.2M270,925 sh
WealthTrust Axiom LLC
$1.1M254,108 sh
VANGUARD CAPITAL MANAGEMENT LLC
$852.2K194,125 sh
Archon Capital Management LLC
$688.4K156,805 sh
MORGAN STANLEY
$631.3K143,794 sh
Stonepine Capital Management, LLC
$439.0K100,000 sh
HighTower Advisors, LLC
$423.9K96,565 sh

Fund	Value	Shares
NEEDHAM INVESTMENT MANAGEMENT LLC	$7.3M	1,670,550
MYDA Advisors LLC	$1.8M	400,000
Nantahala Capital Management, LLC	$1.2M	280,000
Bleichroeder LP	$1.2M	270,925
WealthTrust Axiom LLC	$1.1M	254,108
VANGUARD CAPITAL MANAGEMENT LLC	$852.2K	194,125
Archon Capital Management LLC	$688.4K	156,805
MORGAN STANLEY	$631.3K	143,794
Stonepine Capital Management, LLC	$439.0K	100,000
HighTower Advisors, LLC	$423.9K	96,565

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put POCI on your watchlist

Track score changes the day PRECISION OPTICS CORPORATION, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is POCI a good stock to buy?

13F Pro's AI-powered analysis of PRECISION OPTICS CORPORATION, INC. (POCI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for POCI are available on the POCI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own POCI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling POCI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PRECISION OPTICS CORPORATION, INC.'s investment landscape.